{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:38:49Z","timestamp":1789958329438,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T00:00:00Z","timestamp":1754611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"DOI":"10.1007\/s10585-025-10368-9","type":"journal-article","created":{"date-parts":[[2025,8,8]],"date-time":"2025-08-08T07:46:48Z","timestamp":1754639208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Targeting metabolic and epigenetic reprogramming in metastatic fumarate hydratase-deficient renal cell carcinoma"],"prefix":"10.1007","volume":"42","author":[{"given":"Nadja","family":"K\u00fchrer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Huebner-Resch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Mayr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Agaimy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Kronbichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Schmidinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Pichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,8]]},"reference":[{"issue":"5","key":"10368_CR1","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","volume":"82","author":"H Moch","year":"2022","unstructured":"Moch H, Amin MB, Berney DM, Comp\u00e9rat EM, Gill AJ, Hartmann A et al (2022) The 2022 World Health Organization classification of tumours of the urinary system and male genital organs\u2014part a: renal, penile, and testicular tumours. Eur Urol 82(5):458\u2013468","journal-title":"Eur Urol"},{"issue":"12","key":"10368_CR2","doi-asserted-by":"publisher","first-page":"906014","DOI":"10.3389\/fonc.2022.906014","volume":"15","author":"AK Lindner","year":"2022","unstructured":"Lindner AK, Tulchiner G, Seeber A, Siska PJ, Thurnher M, Pichler R (2022) Targeting strategies in the treatment of fumarate hydratase deficient renal cell carcinoma. Front Oncol 15(12):906014","journal-title":"Front Oncol"},{"issue":"10","key":"10368_CR3","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1136\/jclinpath-2021-207830","volume":"74","author":"RE Zyla","year":"2021","unstructured":"Zyla RE, Hodgson A (2021) Gene of the month: FH. J Clin Pathol 74(10):615\u2013619","journal-title":"J Clin Pathol"},{"issue":"2","key":"10368_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.eururo.2022.05.029","volume":"83","author":"Y Xu","year":"2023","unstructured":"Xu Y, Kong W, Cao M, Wang J, Wang Z, Zheng L et al (2023) Genomic profiling and response to immune checkpoint inhibition plus tyrosine kinase inhibition in FH-deficient renal cell carcinoma. Eur Urol 83(2):163\u2013172","journal-title":"Eur Urol"},{"issue":"23","key":"10368_CR5","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1056\/NEJMoa2200900","volume":"392","author":"R Srinivasan","year":"2025","unstructured":"Srinivasan R, Gurram S, Singer EA, Sidana A, Al Harthy M, Ball MW, Friend JC, Mac L, Purcell E, Vocke CD, Ricketts CJ, Kong HH, Cowen EW, Malayeri AA, Shih JH, Merino MJ, Linehan WM (2025) Bevacizumab and Erlotinib in hereditary and sporadic papillary kidney cancer. N Engl J Med 392(23):2346\u20132356. https:\/\/doi.org\/10.1056\/NEJMoa2200900","journal-title":"N Engl J Med"},{"issue":"2","key":"10368_CR6","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1158\/1535-7163.MCT-24-0225","volume":"24","author":"SS Najera","year":"2025","unstructured":"Najera SS, Ricketts CJ, Schmidt LS, Medina JI, Saito K, Ileva L et al (2025) Targeting NAD+ metabolism vulnerability in FH-deficient hereditary leiomyomatosis and renal cell carcinoma with the novel NAMPT inhibitor OT-82. Mol Cancer Ther 24(2):200\u2013213","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10368_CR7","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/PAS.0000000000001372","volume":"44","author":"HD Lau","year":"2020","unstructured":"Lau HD, Chan E, Fan AC, Kunder CA, Williamson SR, Zhou M et al (2020) A clinicopathologic and molecular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients. Am J Surg Pathol 44(1):98\u2013110","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10368_CR8","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1038\/s41416-023-02412-w","volume":"129","author":"L Valcarcel-Jimenez","year":"2023","unstructured":"Valcarcel-Jimenez L, Frezza C (2023) Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism. Br J Cancer 129(10):1546\u20131557","journal-title":"Br J Cancer"},{"key":"10368_CR9","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1038\/s41379-018-0017-7","volume":"31","author":"M Muller","year":"2018","unstructured":"Muller M, Guillaud-Bataille M, Salleron J et al (2018) Pattern multiplicity and fumarate hydratase (FH)\/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration. Mod Pathol 31:974\u2013983","journal-title":"Mod Pathol"},{"key":"10368_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1097\/PAS.0000000000000163","volume":"38","author":"Y-B Chen","year":"2014","unstructured":"Chen Y-B, Brannon AR, Toubaji A et al (2014) Hereditary leiomyomatosis and renal cell carcinoma syndrome\u2013associated renal cancer: recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry. Am J Surg Pathol 38:627\u2013637","journal-title":"Am J Surg Pathol"},{"issue":"664","key":"10368_CR11","doi-asserted-by":"publisher","first-page":"4436","DOI":"10.1126\/scisignal.abc4436","volume":"14","author":"DR Crooks","year":"2021","unstructured":"Crooks DR, Maio N, Lang M, Ricketts CJ, Vocke CD, Gurram S et al (2021) Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer. Sci Signal 14(664):4436","journal-title":"Sci Signal"},{"issue":"4","key":"10368_CR12","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.celrep.2017.09.092","volume":"21","author":"PA Tyrakis","year":"2017","unstructured":"Tyrakis PA, Yurkovich ME, Sciacovelli M, Papachristou EK, Bridges HR, Gaude E et al (2017) Fumarate Hydratase loss causes combined respiratory chain defects. Cell Rep 21(4):1036\u20131047","journal-title":"Cell Rep"},{"issue":"1","key":"10368_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.semcdb.2019.05.002","volume":"98","author":"C Schmidt","year":"2020","unstructured":"Schmidt C, Sciacovelli M, Frezza C (2020) Fumarate hydratase in cancer: a multifaceted tumour suppressor. Semin Cell Dev Biol 98(1):15\u201325","journal-title":"Semin Cell Dev Biol"},{"issue":"7363","key":"10368_CR14","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nature10363","volume":"477","author":"C Frezza","year":"2011","unstructured":"Frezza C, Zheng L, Folger O, Rajagopalan KN, MacKenzie ED, Jerby L et al (2011) Haem oxygenase is synthetically lethal with the tumour suppressor fumarate hydratase. Nature 477(7363):225\u2013228","journal-title":"Nature"},{"issue":"10","key":"10368_CR15","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1038\/s41568-018-0054-z","volume":"18","author":"R Keshet","year":"2018","unstructured":"Keshet R, Szlosarek P, Carracedo A, Erez A (2018) Rewiring urea cycle metabolism in cancer to support anabolism. Nat Rev Cancer 18(10):634\u2013645","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"10368_CR16","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.celrep.2013.04.006","volume":"3","author":"J Adam","year":"2013","unstructured":"Adam J, Yang M, Bauerschmidt C, Kitagawa M, O\u2019Flaherty L, Maheswaran P et al (2013) A role for cytosolic fumarate hydratase in urea cycle metabolism and renal neoplasia. Cell Rep 3(5):1440\u20131448","journal-title":"Cell Rep"},{"issue":"12","key":"10368_CR17","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1002\/ijc.25202","volume":"126","author":"B Delage","year":"2010","unstructured":"Delage B, Fennell DA, Nicholson L, McNeish I, Lemoine NR, Crook T et al (2010) Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer. Int J Cancer 126(12):2762\u20132772","journal-title":"Int J Cancer"},{"key":"10368_CR18","doi-asserted-by":"publisher","unstructured":"Wilde BR, Chakraborty N, Matulionis N, Hernandez S, Ueno D, Gee ME, et al. (2023) FH variant pathogenicity promotes purine salvage pathway dependence in kidney cancer [Internet]. bioRxiv; 2023 [cited 2025 Apr 14]. pp. 2022.08.15.504023. Available from: https:\/\/doi.org\/10.1101\/2022.08.15.504023v3","DOI":"10.1101\/2022.08.15.504023v3"},{"issue":"4","key":"10368_CR19","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.ccr.2011.09.006","volume":"20","author":"J Adam","year":"2011","unstructured":"Adam J, Hatipoglu E, O\u2019Flaherty L, Ternette N, Sahgal N, Lockstone H et al (2011) Renal cyst formation in Fh1-deficient mice is independent of the Hif\/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell 20(4):524\u2013537","journal-title":"Cancer Cell"},{"issue":"88","key":"10368_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.freeradbiomed.2015.05.034","volume":"1","author":"P Canning","year":"2015","unstructured":"Canning P, Sorrell FJ, Bullock AN (2015) Structural basis of Keap1 interactions with Nrf2. Free Radic Biol Med 1(88):101\u2013107","journal-title":"Free Radic Biol Med"},{"issue":"34","key":"10368_CR21","doi-asserted-by":"publisher","first-page":"20700","DOI":"10.1074\/jbc.R115.675652","volume":"290","author":"FP Guengerich","year":"2015","unstructured":"Guengerich FP (2015) Introduction: metals in biology: \u03b1-ketoglutarate\/iron-dependent dioxygenases*. J Biol Chem 290(34):20700\u201320701","journal-title":"J Biol Chem"},{"issue":"12","key":"10368_CR22","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/s41568-020-00303-3","volume":"20","author":"JA Losman","year":"2020","unstructured":"Losman JA, Koivunen P, Kaelin WG (2020) 2-Oxoglutarate-dependent dioxygenases in cancer. Nat Rev Cancer 20(12):710\u2013726","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10368_CR23","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.tcb.2020.09.010","volume":"31","author":"SC Baksh","year":"2021","unstructured":"Baksh SC, Finley LWS (2021) Metabolic coordination of cell fate by \u03b1-ketoglutarate-dependent dioxygenases. Trends Cell Biol 31(1):24\u201336","journal-title":"Trends Cell Biol"},{"issue":"5","key":"10368_CR24","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","volume":"5","author":"GN Masoud","year":"2015","unstructured":"Masoud GN, Li W (2015) HIF-1\u03b1 pathway: role, regulation and intervention for cancer therapy. Acta Pharm Sin B 5(5):378\u2013389","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"10368_CR25","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1074\/jbc.M608337200","volume":"282","author":"KS Hewitson","year":"2007","unstructured":"Hewitson KS, Li\u00e9nard BMR, McDonough MA, Clifton IJ, Butler D, Soares AS et al (2007) Structural and mechanistic studies on the inhibition of the hypoxia-inducible transcription factor hydroxylases by tricarboxylic acid cycle intermediates. J Biol Chem 282(5):3293\u20133301","journal-title":"J Biol Chem"},{"issue":"13","key":"10368_CR26","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1158\/1078-0432.CCR-13-0304","volume":"19","author":"WM Linehan","year":"2013","unstructured":"Linehan WM, Rouault TA (2013) Molecular pathways: fumarate hydratase-deficient kidney cancer: targeting the Warburg effect in cancer. Clin Cancer Res Off J Am Assoc Cancer Res 19(13):3345\u20133352","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10368_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1416472\/full","author":"J Zhao","year":"2024","unstructured":"Zhao J, Jin D, Huang M, Ji J, Xu X, Wang F et al (2024) Glycolysis in the tumor microenvironment: a driver of cancer progression and a promising therapeutic target. Front Cell Dev Biol. https:\/\/doi.org\/10.3389\/fcell.2024.1416472\/full","journal-title":"Front Cell Dev Biol"},{"issue":"36","key":"10368_CR28","doi-asserted-by":"publisher","first-page":"25903","DOI":"10.1074\/jbc.M603414200","volume":"281","author":"XH Peng","year":"2006","unstructured":"Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L (2006) Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1\u03b1 signal pathways increases resistance to apoptosis by up-regulating survivin gene expression *. J Biol Chem 281(36):25903\u201325914","journal-title":"J Biol Chem"},{"issue":"12","key":"10368_CR29","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1101\/gad.191056.112","volume":"26","author":"M Xiao","year":"2012","unstructured":"Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H et al (2012) Inhibition of \u03b1-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 26(12):1326\u20131338","journal-title":"Genes Dev"},{"issue":"9","key":"10368_CR30","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1038\/ncb3209","volume":"17","author":"Y Jiang","year":"2015","unstructured":"Jiang Y, Qian X, Shen J, Wang Y, Li X, Liu R et al (2015) Local generation of fumarate promotes DNA repair through inhibition of histone H3 demethylation. Nat Cell Biol 17(9):1158\u20131168","journal-title":"Nat Cell Biol"},{"issue":"2","key":"10368_CR31","doi-asserted-by":"publisher","first-page":"e430734","DOI":"10.1200\/EDBK_430734","volume":"44","author":"RM Saliby","year":"2024","unstructured":"Saliby RM, Saad E, Kashima S, Schoenfeld DA, Braun DA (2024) Update on biomarkers in renal cell carcinoma. Am Soc Clin Oncol Educ Book 44(2):e430734. https:\/\/doi.org\/10.1200\/EDBK_430734. (PMID: 38207251)","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"4","key":"10368_CR32","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1158\/1078-0432.CCR-23-1892","volume":"30","author":"I Lyskj\u00e6r","year":"2024","unstructured":"Lyskj\u00e6r I, Iisager L, Axelsen CT, Nielsen TK, Dyrskj\u00f8t L, Fristrup N (2024) Management of renal cell carcinoma: promising biomarkers and the challenges to reach the clinic. Clin Cancer Res 30(4):663\u2013672. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1892","journal-title":"Clin Cancer Res"},{"issue":"29","key":"10368_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.anndiagpath.2017.04.007","volume":"1","author":"R Alaghehbandan","year":"2017","unstructured":"Alaghehbandan R, Stehlik J, Trpkov K, Magi-Galluzzi C, Condom Mundo E, Pane Foix M et al (2017) Programmed death-1 (PD-1) receptor\/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma. Ann Diagn Pathol 1(29):17\u201322","journal-title":"Ann Diagn Pathol"},{"issue":"2","key":"10368_CR34","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3760\/cma.j.cn112151-20230905-00132","volume":"53","author":"S Chen","year":"2024","unstructured":"Chen S, Ban CR, Zhang XT, Chen YP, Ren CH, Chen H (2024) Expression of programmed cell death ligand 1 and clinicopathological and immunological characteristics in fumarate hydratase-deficient renal cell carcinoma. Zhonghua Bing Li Xue Za Zhi 53(2):155\u2013161. https:\/\/doi.org\/10.3760\/cma.j.cn112151-20230905-00132","journal-title":"Zhonghua Bing Li Xue Za Zhi"},{"issue":"10","key":"10368_CR35","doi-asserted-by":"publisher","first-page":"2910","DOI":"10.1158\/1078-0432.CCR-20-4367","volume":"27","author":"JP Gleeson","year":"2021","unstructured":"Gleeson JP, Nikolovski I, Dinatale R, Zucker M, Knezevic A, Patil S et al (2021) Comprehensive molecular characterization and response to therapy in fumarate hydratase-deficient renal cell carcinoma. Clin Cancer Res 27(10):2910\u20132919","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10368_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14562-6","volume":"25","author":"J Bai","year":"2025","unstructured":"Bai J, Huang J, Ye Y, Lin J, Wen Y, Cai Z, Chen P, Shangguan T, Zou G, Qiu Q, Chen R, Liu R, Cai W, Zhu S, Chen J, Li X (2025) Clinicopathologic and prognosis of 30 patients with FH-deficient renal cell carcinoma: a single-center retrospective study. BMC Cancer 25(1):1152. https:\/\/doi.org\/10.1186\/s12885-025-14562-6","journal-title":"BMC Cancer"},{"issue":"21","key":"10368_CR37","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.21.01944","volume":"40","author":"CH Lee","year":"2022","unstructured":"Lee CH, Voss MH, Carlo MI, Chen YB, Zucker M, Knezevic A et al (2022) Phase II trial of cabozantinib plus nivolumab in patients with non\u2013clear-cell renal cell carcinoma and genomic correlates. J Clin Oncol 40(21):2333\u20132341","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10368_CR38","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1200\/JCO.2023.41.6_suppl.685","volume":"41","author":"X Zhang","year":"2023","unstructured":"Zhang X, Liu H, Zhang Y, Zhao J, Chen Y, Sun G et al (2023) Phase II multi-center study of sintilimab in combination with axitinib in patients with advanced fumarate hydratase-deficient renal cell carcinoma. J Clin Oncol. 41(6_suppl):685\u2013685","journal-title":"J Clin Oncol."},{"issue":"5_suppl","key":"10368_CR39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1200\/JCO.2025.43.5_suppl.443","volume":"43","author":"W Kong","year":"2025","unstructured":"Kong W, Wu G, Xu Y, Wang Z, Zhang J (2025) Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: a single-center, single-arm, phase II study. J Clin Oncol. 43(5_suppl):443\u2013443","journal-title":"J Clin Oncol."},{"issue":"11","key":"10368_CR40","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1158\/1078-0432.CCR-23-2760","volume":"30","author":"J Chen","year":"2024","unstructured":"Chen J, Hu X, Zhao J, Yin X, Zheng L, Guo J et al (2024) Memory\/active T-cell activation is associated with immunotherapeutic response in fumarate hydratase-deficient renal cell carcinoma. Clin Cancer Res 30(11):2571\u20132581","journal-title":"Clin Cancer Res"},{"issue":"151","key":"10368_CR41","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ejca.2021.04.009","volume":"1","author":"L Carril-Ajuria","year":"2021","unstructured":"Carril-Ajuria L, Colomba E, Cerbone L, Romero-Ferreiro C, Crouzet L, Laguerre B et al (2021) Response to systemic therapy in fumarate hydratase\u2013deficient renal cell carcinoma. Eur J Cancer 1(151):106\u2013114","journal-title":"Eur J Cancer"},{"issue":"113","key":"10368_CR42","doi-asserted-by":"publisher","first-page":"109054","DOI":"10.1016\/j.ijscr.2023.109054","volume":"1","author":"MR Samar","year":"2023","unstructured":"Samar MR, Khan W, Rashid YA, Mohammad ATV (2023) Unmasking the enigma: a case of fumarate hydratase-deficient renal cell carcinoma. Int J Surg Case Rep 1(113):109054","journal-title":"Int J Surg Case Rep"},{"issue":"4","key":"10368_CR43","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.euo.2023.10.017","volume":"7","author":"RR Kotecha","year":"2024","unstructured":"Kotecha RR, Doshi SD, Knezevic A, Chaim J, Chen Y, Jacobi R et al (2024) A phase 2 trial of talazoparib and avelumab in genomically defined metastatic kidney cancer. Eur Urol Oncol 7(4):804\u2013811","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"10368_CR44","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.4143\/crt.2019.086","volume":"51","author":"Y Choi","year":"2019","unstructured":"Choi Y, Keam B, Kim M, Yoon S, Kim D, Choi JG et al (2019) Bevacizumab Plus Erlotinib combination therapy for advanced hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma: a multicenter retrospective analysis in Korean patients. Cancer Res Treat 51(4):1549\u20131556","journal-title":"Cancer Res Treat"}],"container-title":["Clinical & Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10368-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-025-10368-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10368-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T05:16:32Z","timestamp":1760073392000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-025-10368-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,8]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["10368"],"URL":"https:\/\/doi.org\/10.1007\/s10585-025-10368-9","relation":{},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,8]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"47"}}